Table.

Characteristics of the Present and Previously Reported Patients with CCS Associated with MN.

References	Age/Sex	Onset of MN at the diagnosis of CCS	Treatments for CCS	Additional treatments for MN	Patient outcome†
10	41/M	5 years before	Low anterior resection due to rectal adenocarcinoma	None	Remission‡
11	64/M	10 months after	Right hemicolectomy due to ascending colon mucinous adenocarcinoma and oral PSL (40 mg/day, tapered later)	Reintroduction of PSL	Remission‡
12	17/M	A few months after	CyA	CyA	Remission‡
13	59/M	30 years before	Total gastrectomy due to gastric tubular adenocarcinoma	None	ND
14	71/M	12 months after	PSL and azathioprine (75 mg/day)	CyA and rituximab in addition to azathioprine	Remission§
The present case	47/M	29 months after	PSL	Pulse methylprednisolone (tapered later) and CyA	Remission

^†Remission was defined as both regression of clinical symptoms of CCS and proteinuria. ^‡No endoscopic findings after treatment were described. ^§In this case, symptoms of CCS improved after additional CyA treatment, whereas his proteinuria did not resolve. Rituximab resulted in a regression of his MN and endoscopic findings. CCS: Cronkhite-Canada Syndrome, MN: membranous nephropathy, CyA: cyclosporine A, PSL: prednisolone, M: male, ND: not described